259 related articles for article (PubMed ID: 28304025)
1. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Li A; Yadav R; White JK; Herroon MK; Callahan BP; Podgorski I; Turro C; Scott EE; Kodanko JJ
Chem Commun (Camb); 2017 Mar; 53(26):3673-3676. PubMed ID: 28304025
[TBL] [Abstract][Full Text] [Related]
2. Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.
Toupin N; Steinke SJ; Nadella S; Li A; Rohrabaugh TN; Samuels ER; Turro C; Sevrioukova IF; Kodanko JJ
J Am Chem Soc; 2021 Jun; 143(24):9191-9205. PubMed ID: 34110801
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic Ruthenium(II) Complexes Containing a Dangling Pyridine: Selectivity for Diseased Cells Mediated by pH-Dependent DNA Binding.
Sangeetha S; Murali M
Inorg Chem; 2022 Feb; 61(6):2864-2882. PubMed ID: 35099196
[TBL] [Abstract][Full Text] [Related]
4. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
5. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
[TBL] [Abstract][Full Text] [Related]
6. Pyrazole appended quinoline-BODIPY based arene ruthenium complexes: their anticancer activity and potential applications in cellular imaging.
Paitandi RP; Sharma V; Singh VD; Dwivedi BK; Mobin SM; Pandey DS
Dalton Trans; 2018 Dec; 47(48):17500-17514. PubMed ID: 30507985
[TBL] [Abstract][Full Text] [Related]
7. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
8. Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Kuzikov AV; Dugin NO; Stulov SV; Shcherbinin DS; Zharkova MS; Tkachev YV; Timofeev VP; Veselovsky AV; Shumyantseva VV; Misharin AY
Steroids; 2014 Oct; 88():66-71. PubMed ID: 24971814
[TBL] [Abstract][Full Text] [Related]
9. A nuclear permeable Ru(ii)-based photoactivated chemotherapeutic agent towards a series of cancer cells: in vitro and in vivo studies.
Tian N; Feng Y; Sun W; Lu J; Lu S; Yao Y; Li C; Wang X; Zhou Q
Dalton Trans; 2019 May; 48(19):6492-6500. PubMed ID: 30994660
[TBL] [Abstract][Full Text] [Related]
10. Rhodamine-modified fluorescent half-sandwich iridium and ruthenium complexes: potential application as bioimaging and anticancer agents.
Ma W; Guo L; Tian Z; Zhang S; He X; Li J; Yang Y; Liu Z
Dalton Trans; 2019 Apr; 48(15):4788-4793. PubMed ID: 30892340
[TBL] [Abstract][Full Text] [Related]
11. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.
Tian M; Li J; Zhang S; Guo L; He X; Kong D; Zhang H; Liu Z
Chem Commun (Camb); 2017 Nov; 53(95):12810-12813. PubMed ID: 29143019
[TBL] [Abstract][Full Text] [Related]
12. Comparison of [17(20)E]-21-Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth.
Zolottsev VA; Tkachev YV; Latysheva AS; Kostin VA; Novikov RA; Timofeev VP; Morozevich GE; Kuzikov AV; Shumyantseva VV; Misharin AY
Steroids; 2018 Jan; 129():24-34. PubMed ID: 29183745
[TBL] [Abstract][Full Text] [Related]
13. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, Characterization, and Biological Properties of Steroidal Ruthenium(II) and Iridium(III) Complexes Based on the Androst-16-en-3-ol Framework.
Koch V; Meschkov A; Feuerstein W; Pfeifer J; Fuhr O; Nieger M; Schepers U; Bräse S
Inorg Chem; 2019 Dec; 58(23):15917-15926. PubMed ID: 31714764
[TBL] [Abstract][Full Text] [Related]
15. π-Expansive Heteroleptic Ruthenium(II) Complexes as Reverse Saturable Absorbers and Photosensitizers for Photodynamic Therapy.
Wang L; Yin H; Jabed MA; Hetu M; Wang C; Monro S; Zhu X; Kilina S; McFarland SA; Sun W
Inorg Chem; 2017 Mar; 56(6):3245-3259. PubMed ID: 28263079
[TBL] [Abstract][Full Text] [Related]
16. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes.
Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN
Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
[TBL] [Abstract][Full Text] [Related]
18. Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents.
Pal M; Nandi U; Mukherjee D
Eur J Med Chem; 2018 Apr; 150():419-445. PubMed ID: 29547831
[TBL] [Abstract][Full Text] [Related]
19. To cage or to be caged? The cytotoxic species in ruthenium-based photoactivated chemotherapy is not always the metal.
Cuello-Garibo JA; Meijer MS; Bonnet S
Chem Commun (Camb); 2017 Jun; 53(50):6768-6771. PubMed ID: 28597879
[TBL] [Abstract][Full Text] [Related]
20. Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.
Arora K; Herroon M; Al-Afyouni MH; Toupin NP; Rohrabaugh TN; Loftus LM; Podgorski I; Turro C; Kodanko JJ
J Am Chem Soc; 2018 Oct; 140(43):14367-14380. PubMed ID: 30278123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
